I think that now with an even broader activity profile, and assuming there is nothing new on the safety front ARQ197 is getting even more attarctive.
In other words, Arqule is now in a better position than last week , but is worth ~15% less, so the rationale in buying now is even stronger.
I don’t know if you can call it a once in a lifetime opportunity because it’s a small biotech and uncertainty is still a primary factor, especially bearing in mind that Arqule has only one asset and how will the new platform pan out remains to be seen. Nevertheless, we’re lookign at a $117 mil company, who is about to sign a deal that includes 40-60$ mil in cash and tens of millions in development costs that will be taken by the partner. I think that’s an opportunity but I wouldn’t bet the farm on a single stock, let alone a small biotech with a limited clinical pipeline.

Ohad

Despite the recent announcement and the “imminent” deal the stock is still behaving very badly.
Perhaps there is something we are missing, or is it a once in a lifetime opportunity?

TIA
Dave